Ignite Creation Date:
2025-12-25 @ 12:59 AM
Ignite Modification Date:
2026-04-21 @ 7:00 PM
Study NCT ID:
NCT02413593
Status:
COMPLETED
Last Update Posted:
2018-11-16
First Post:
2015-04-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04
Start Date Type:
None
Primary Completion Date:
2015-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-01
Completion Date Type:
ACTUAL
First Submit Date:
2015-04-07
First Submit QC Date:
None
Study First Post Date:
2015-04-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-12-22
Results First Submit QC Date:
None
Results First Post Date:
2017-02-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-10-19
Last Update Post Date:
2018-11-16
Last Update Post Date Type:
ACTUAL